thyroid cancer
Conditions
Interventions
The group of Radioiodine-poor efficacy:anlotinib combined with 131I
The group of Radioiodine-refractory:anlotinib
Sponsors
The Second Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The patients voluntarily joined the study and signed the informed consent; 2. Aged 18-75 years, gender is not limited; 3. Patients with advanced metastatic differentiated thyroid cancer diagnosed by histopathology; 4. The patient is diagnosed with RAIR-DTC or with poor efficacy of iodine treatment; 5. ECOG score 0-1 points.
Exclusion criteria
Exclusion criteria: 1. Those who have used anti-angiogenic drugs such as Sorafenib and Lenvatinib in the past or are allergic to anti-angiogenic drugs; 2. Currently participating in interventional clinical research treatment, or have received other investigational drugs or used investigational device treatment within 4 weeks before the first dose; 3. Received Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects within 2 weeks before the first administration; 4. Pregnant or lactating patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;Progression-free survival;Overall survival;Radioactive iodine uptake rate;131I whole body imaging; | — |
Countries
China
Contacts
Public ContactZhang Wei
Outcome results
None listed